BMS-1 PD-1/PD-L1 inhibitor 1|cas:1675201-83-8|西域试剂

BMS-1 PD-1/PD-L1 inhibitor 1,99.56%

产品编号：Bellancom-19991| CAS NO：1675201-83-8| 分子式：C₂₉H₃₃NO₅| 分子量：475.58

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-19991	￥1200.00	杭州北京（现货）
Bellancom-19991	￥1900.00	杭州北京（现货）
Bellancom-19991	￥3800.00	杭州北京（现货）
Bellancom-19991	￥5500.00	杭州北京（现货）
Bellancom-19991	￥8800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BMS-1 PD-1/PD-L1 inhibitor 1

产品介绍

BMS-1 是 PD-1/PD-L1 蛋白质/蛋白质相互作用的抑制剂，IC₅₀ 为 6 到 100 nM。

生物活性

BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC₅₀ between 6 and 100 nM).

体外研究

Since PD-1 mediated the exhaustion of natural killer (NK) cell by binding to its ligand PD-L1, BMS-1 (PD-1/PD-L1 inhibitor 1) (1 μM, 3 days) is used to disturb the interaction between PD-1 and PD-L1. Dexamethasone induced increase of PD-1 expression and decrease of cytotoxicity of the co-cultured NK92 cells are reversed by BMS-1. BMS-1, a small-molecule immune checkpoint inhibitor of PD-1/PD-L1, can be used as a therapeutic strategy for tumor immunotherapy.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	NK cells and HepG2 cells
Concentration:	1 μM
Incubation Time:	3 days
Result:	Disturbed the interaction between PD-1 and PD-L1.

体内研究
(In Vivo)

BMS-1 (500 μg/mL; 100 μL; i.p.) significantly increases the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice with EMT6 cells
Dosage:	500 μg/mL; 100 μL
Administration:	I.p.
Result:	Increased the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group. mVEGF165b combined with MUC1 results significant retardation of the tumor growth.

体内研究

BMS-1 (500 μg/mL; 100 μL; i.p.) significantly increases the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice with EMT6 cells
Dosage:	500 μg/mL; 100 μL
Administration:	I.p.
Result:	Increased the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group. mVEGF165b combined with MUC1 results significant retardation of the tumor growth.

体内研究

BMS-1 (500 μg/mL; 100 μL; i.p.) significantly increases the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice with EMT6 cells
Dosage:	500 μg/mL; 100 μL
Administration:	I.p.
Result:	Increased the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group. mVEGF165b combined with MUC1 results significant retardation of the tumor growth.

性状

Solid

溶解性数据

In Vitro:

Methanol : 25 mg/mL (52.57 mM; Need ultrasonic)

DMSO : 9 mg/mL (18.92 mM; Need ultrasonic and warming)

DMF : 5 mg/mL (10.51 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1027 mL	10.5135 mL	21.0270 mL
5 mM	0.4205 mL	2.1027 mL	4.2054 mL
10 mM	0.2103 mL	1.0513 mL	2.1027 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.10 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.10 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.10 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。